Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

ArriVent Closes $155 Million Round to In-license US Rights for China Drugs

publication date: Mar 27, 2023

Arrivent Biopharma completed an oversubscribed $155 million Series B round to fund its in-licensing of US rights to medications from China and other emerging countries. The Philadelphia company said it would use most of the proceeds to underwrite the cost of a pivotal Phase III trial of its lead product, furmonertinib, a brain penetrating, mutant-specific EGFR kinase inhibitor in-licensed from Shanghai's Allist Pharma. ArriVent broke out of stealth mode last year with the furmonertinib rights and an impressive $150 million in initial funding from China investors. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital